Speaker Details

Joel M. Gelfand, MD, MSCE, FAAD

Joel M. Gelfand, MD, MSCE, FAAD

SESSIONS

S023 Psoriasis: Modern Therapeutic Approaches
Mar 8, 2025 9:00 AM - 12:00 PM Valencia Ballroom D
S028 Late-breaking Research: Session 1
Mar 8, 2025 9:00 AM - 12:00 PM Chapin Theater - Level III
S040 Late-Breaking Research: Session 2
Mar 8, 2025 1:00 PM - 4:00 PM Chapin Theater - Level III

HANDOUTS

Login to view handouts

DISCLOSURES

AbbVie – Consultant(Fees); Amgen – Investigator(Grants/Research Funding); Artax Biopharma – Data Safety Monitoring Board(Fees); BMS – Consultant(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); CellDex – Data Safety Monitoring Board(Fees); Daavlin Company – Other(Equipment); FIDE – Consultant(Fees); Healio – Other(Fees); Inmagene Biopharmaceuticals – Data Safety Monitoring Board(Fees); International Psoriasis Council – Board of Directors(No Compensation Received); Janssen Pharmaceuticals, Inc – Consultant(Honoraria); Leo Pharma Inc – Consultant(Fees); Maui Derm – Speaker/Faculty Education(Fees); Medical Dermatology Society – Board of Directors(No Compensation Received); Moonlake – Data Safety Monitoring Board(Fees); National Psoriasis Foundation – Investigator(Grants/Research Funding); Neuroderm LTD – Other(Fees); Novartis Pharmaceuticals Corp. – Consultant(Honoraria), Investigator(Grants/Research Funding); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); UCB – Other(Fees); Veolia North America – Consultant(Fees);